Molecular Partners AG (NASDAQ: MOLN) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT MOLECULAR PARTNERS AG

Molecular Partners AG (NASDAQ: MOLN)
Listen to this Section


$5.04
-0.0050 ( -0.55% ) 1.6K

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Market Data


Open $5.04
Previous Close $5.04
Volume 1.6K
Market Cap $185.79M
Day Range $5.00 - $5.06
52 Week Range $3.32 - $12.70
Shares Outstanding 36.86M
Change % -0.55%
Net Change ▼ -0.0050
Insider Ownership N/A
Exchange NASDAQ
Sector Healthcare
Industry
IPO Year 2021
Country Switzerland
Under Writer J.P. Morgan, Leerink Partners, TD Cowen, RBC Capital Markets, Kempen, more

Insider Ownership Transactions

Total Amount Purchased: 0.00

Date Type Amount Purchased Purchaser
No records found.

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
6-k Form 6-K 2 Jan 13, 2025
6-k Form 6-K 2 Jan 13, 2025
6-k Form 6-K 4 Oct 31, 2024
sc Insider transactions 1 Oct 29, 2024
6-k Form 6-K 8 Oct 28, 2024
424b5 Other 3 Oct 25, 2024
6-k Form 6-K 3 Oct 22, 2024
6-k Form 6-K 62 Aug 26, 2024
s-8 Registration statements 6 Jun 26, 2024
6-k Form 6-K 4 Jun 14, 2024

Latest News


× Before browsing our site, please accept our cookies policy